文献速递癫痫

芬氟拉明治疗Lennox-Gastaut综合征相关癫痫发作的疗效与安全性:一项随机临床试验

Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2022-01-01

这项多中心、双盲、安慰剂对照、平行组随机临床试验纳入263例2至35岁Lennox-Gastaut综合征患者,评估芬氟拉明0.7 mg/kg/d与0.2 mg/kg/d相比安慰剂的疗效与安全性。主要终点分析显示,0.7 mg/kg/d芬氟拉明组跌倒发作频率较基线的降幅比安慰剂组多降低19.9个百分点(95% CI,-31.0至-8.7个百分点;P=0.001),达到50%及以上应答的患者比例更高(25%对10%,P=0.02),常见不良事件包括食欲下降、嗜睡和疲劳;未观察到心脏瓣膜病或肺动脉高压病例。

要点

  • 0.7 mg/kg/d芬氟拉明组跌倒发作频率较基线的降幅比安慰剂组多降低19.9个百分点(95% CI,-31.0至-8.7个百分点;P=0.001)。
  • 0.7 mg/kg/d芬氟拉明组25%(22/87)患者达到50%及以上应答,安慰剂组为10%(9/87)(P=0.02)。
  • 常见治疗中出现的不良事件包括食欲下降22%(59例)、嗜睡13%(33例)和疲劳13%(33例)。

核心结论

  • 在Lennox-Gastaut综合征患者中,芬氟拉明相比安慰剂可显著更大幅度减少跌倒发作,且可能对出现全面性强直-阵挛发作的患者尤其有利。

研究设计与样本

  • 多中心、双盲、安慰剂对照、平行组随机临床试验,于2017年11月27日至2019年10月25日进行,试验持续时间20周,在北美、欧洲和澳大利亚的65个研究中心入组患者。
  • 纳入年龄2至35岁、确诊Lennox-Gastaut综合征且4周基线期内每周至少2次跌倒发作的患者,共263例(中位[范围]年龄13[2-35]岁;男性146例[56%])。
  • 患者随机分配至0.7 mg/kg/d芬氟拉明组(n=87)、0.2 mg/kg/d芬氟拉明组(n=89)或安慰剂组(n=87);经2周滴定期后,按随机剂量继续治疗12周。

主要发现

  • 跌倒发作频率相对基线的中位降幅:0.7 mg/kg/d芬氟拉明组26.5个百分点,0.2 mg/kg/d芬氟拉明组14.2个百分点,安慰剂组7.6个百分点。
  • 0.7 mg/kg/d芬氟拉明组相比安慰剂组,跌倒发作相对基线变化的估计中位差值为-19.9个百分点(95% CI,-31.0至-8.7个百分点;P=0.001)。
  • 达到50%及以上应答的患者比例:0.7 mg/kg/d芬氟拉明组25%(22/87) vs 安慰剂组10%(9/87)(P=0.02)。
  • 研究者与照护者在临床总体印象改善量表上评为明显改善或非常明显改善的患者比例:0.7 mg/kg/d芬氟拉明组26%(21例) vs 安慰剂组6%(5例)(P=0.001)。
  • 对芬氟拉明应答最明显的发作亚型为全面性强直-阵挛发作(120/263[46%]),其频率在0.7 mg/kg/d芬氟拉明组降低45.7%,在0.2 mg/kg/d芬氟拉明组降低58.2%,而安慰剂组增加3.7%。

关键数值与推荐

  • 0.7 mg/kg/d芬氟拉明组跌倒发作频率相对基线变化与安慰剂组的估计中位差值为-19.9个百分点(95% CI,-31.0至-8.7个百分点;P=0.001)。
  • 0.7 mg/kg/d芬氟拉明组达到50%及以上应答的患者为25%(22/87),安慰剂组为10%(9/87)(P=0.02)。
  • 常见治疗中出现的不良事件:食欲下降22%(59例),嗜睡13%(33例),疲劳13%(33例)。
  • 未观察到心脏瓣膜病或肺动脉高压病例。

临床怎么用

  • 作者认为,在Lennox-Gastaut综合征患者中,芬氟拉明相比安慰剂可显著更大幅度减少跌倒发作,且可能对出现全面性强直-阵挛发作的患者尤其有利。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: New treatment options are needed for patients with Lennox-Gastaut syndrome (LGS), a profoundly impairing, treatment-resistant, developmental and epileptic encephalopathy. OBJECTIVE: To evaluate the efficacy and safety of fenfluramine in patients with LGS. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted from November 27, 2017, to October 25, 2019, and had a 20-week trial duration. Patients were enrolled at 65 study sites in North America, Europe, and Australia. Included patients were aged 2 to 35 years with confirmed diagnosis of LGS and experienced 2 or more drop seizures per week during the 4-week baseline. Using a modified intent-to-treat method, data analysis was performed from November 27, 2017, to October 25, 2019. The database lock date was January 30, 2020, and the date of final report was September 11, 2021. INTERVENTIONS: Patients were randomized to receive either a 0.7-mg/kg/d or 0.2-mg/kg/d (maximum 26 mg/d) dose of fenfluramine or placebo. After titration (2-week period), patients were taking their randomized dose for 12 additional weeks. MAIN OUTCOMES AND MEASURES: Primary efficacy end point was percentage change from baseline in drop seizure frequency in patients who received 0.7 mg/kg/d of fenfluramine vs placebo. RESULTS: A total of 263 patients (median [range] age, 13 [2-35] years; 146 male patients [56%]) were randomized to the 0.7-mg/kg/d fenfluramine group (n = 87), 0.2-mg/kg/d fenfluramine group (n = 89), or placebo group (n = 87). The median percentage reduction in frequency of drop seizures was 26.5 percentage points in the 0.7-mg/kg/d fenfluramine group, 14.2 percentage points in the 0.2-mg/kg/d fenfluramine group, and 7.6 percentage points in the placebo group. The trial met its primary efficacy end point: patients in the 0.7-mg/kg/d fenfluramine group achieved a -19.9 percentage points (95% CI, -31.0 to -8.7 percentage points; P = .001) estimated median difference in drop seizures from baseline vs placebo. More patients in the 0.7-mg/kg/d fenfluramine group achieved a 50% or greater response (22 of 87 [25%]; P = .02) vs placebo (9 of 87 [10%]). Site investigators and caregivers gave a much improved or very much improved rating on the Clinical Global Impression of Improvement scale to more patients in the 0.7-mg/kg/d fenfluramine group than patients in the placebo group (21 [26%] vs 5 [6%]; P = .001). The seizure subtype that appeared most responsive to fenfluramine was generalized tonic-clonic seizure (120 of 263 [46%]), with a decrease in frequency of 45.7% in the 0.7-mg/kg/d fenfluramine group and 58.2% in the 0.2-mg/kg/d fenfluramine group compared with an increase of 3.7% in the placebo group. Most common treatment-emergent adverse events included decreased appetite (59 [22%]), somnolence (33 [13%]), and fatigue (33 [13%]). No cases of valvular heart disease or pulmonary arterial hypertension were observed. CONCLUSIONS AND RELEVANCE: Results of this trial showed that, in patients with LGS, fenfluramine compared with placebo provided a significantly greater reduction in drop seizures and may be a particularly advantageous choice in patients who experience generalized tonic-clonic seizures. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03355209.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Knupp KG, Scheffer IE, Ceulemans B, et al. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 35499850. doi:10.1001/jamaneurol.2022.0829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。